COVID-19 vaccination in patients with multiple sclerosis receiving disease-modifying therapies: pragmatic issues.
Drugs Today (Barc)
; 58(12): 605-620, 2022 Dec.
Article
in English
| MEDLINE | ID: covidwho-2196790
ABSTRACT
The SARS-COV-2 pandemic has been a global public health problem since 2019, with over 400 million reported cases, 6 million deaths, and significant economic and social damage. Overlapping SARS-CoV-2 infection in patients with chronic diseases, such as multiple sclerosis (MS), causes management problems, especially in patients treated with disease-modifying therapies. Studies investigating COVID-19 vaccination effectiveness have shown variability in postvaccination immune response that depends on the patient's background treatment, and special attention is required for anti-CD20 therapies. Existing data on the efficacy of COVID-19 vaccination in patients with MS undergoing disease-modifying treatment are summarized and critically evaluated in this article.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
/
Multiple Sclerosis
Type of study:
Experimental Studies
/
Observational study
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Drugs Today (Barc)
Journal subject:
Occupational Medicine
/
Environmental Health
Year:
2022
Document Type:
Article
Affiliation country:
Dot.2022.58.12.3455368
Similar
MEDLINE
...
LILACS
LIS